Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Biopharma Cred. (BPCR)

Price $0.884 on 22-11-2024 at 17:30:00
Change $0.00 0%
Buy $0.886
Sell $0.884
Buy / Sell BPCR Shares
Last Trade: Unknown 500,000.00 at $0.885
Day's Volume: 1,199,482
Last Close: $0.884
Open: $0.89
ISIN: GB00BDGKMY29
Day's Range $0.884 - $0.892
52wk Range: $0.828 - $0.942
Market Capitalisation: $1,052m
VWAP: $0.886204
Shares in Issue: 1,190m

Recent Trades History Biopharma Cred. (BPCR)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 500,000 $0.885 SI Trade
Negotiated Trade
16:42:10 - 22-Nov-24
Sell* 22,976 $0.884 Uncrossing Trade
16:35:19 - 22-Nov-24
Unknown* 6,990 $0.893357 Ordinary
Currency Conversion
16:21:11 - 22-Nov-24
Buy* 10,710 $0.888 Automatic Execution
15:56:54 - 22-Nov-24
Buy* 18,817 $0.886 Automatic Execution
15:56:54 - 22-Nov-24
Buy* 7,215 $0.886 Ordinary
15:46:15 - 22-Nov-24
Sell* 1,016 $0.884 Automatic Execution
15:31:20 - 22-Nov-24
Buy* 22,561 $0.89 Automatic Execution
15:31:20 - 22-Nov-24
Buy* 32,246 $0.89 Automatic Execution
15:31:20 - 22-Nov-24
Unknown* 21,883 $0.894691 Currency Conversion
Negotiated Trade
15:31:06 - 22-Nov-24

Share Price History for Biopharma Cred.

Time period:
to
Date Open High Low Close Volume

Share News for Biopharma Cred.

UK dividends calendar - next 7 days

22nd Oct 2024 14:20

Read More

UK earnings, trading statements calendar - next 7 days

17th Sep 2024 13:47

Read More

IN BRIEF: BioPharma Credit notes Collegium's Ironshore acquisition

5th Sep 2024 13:49

BioPharma Credit PLC - London-based investment company, focused on the life sciences sector - Notes Collegium Pharmaceutical Inc's announcement that it has closed its acquisition of Ironshore Therapeutics Inc. BioPharma announced in late July the second amendment and restatement of its loan agreement with Collegium, BioPharma Credit Investments V (Master) LP, and BPCR Ltd Partnership, with the BioPharma group providing for a USD645.8 million senior secured term loan to fund the acquisition. The loan comprised a USD320.8 million initial term loan, being tranche A, and a USD325.0 million senior delayed draw one, being tranche B. Company funded its allocated 40% of tranche B, totalling USD130 million, in connection with the successful closing of the acquisition. Also has received its allocation of the additional consideration of 2.25% of the tranche B funding, totalling USD2.9 million. Read More

EARNINGS AND TRADING: Robert Walters swings to loss as sales decline

1st Aug 2024 20:51

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

UK dividends calendar - next 7 days

24th Jul 2024 14:44

Read More

FTSE 100 Latest
Value8,262.08
Change112.81

Login to your account

Forgot Password?

Not Registered